MP Healthcare Venture Management
Boston-based life science venture capital firm that collaborates with healthcare entrepreneurs to develop novel technologies and therapeutics. The firm provides capital and supports portfolio companies through strategic guidance, industry connections and facilitation of corporate collaborations.
MP Healthcare Venture Management
Boston, Massachusetts, United States, North America
Services
Equity financing (early-stage and growth)
Provides early-stage and growth capital to life science companies; supports fundraising rounds (examples on the site include seed and Series A financings).
Strategic guidance and domain expertise
Provides strategic and operational guidance to portfolio companies, including development strategy and long-term company support as cited in portfolio testimonials.
Partnership and collaboration facilitation
Facilitates corporate collaborations, research partnerships and licensing arrangements between portfolio companies and pharmaceutical partners (examples on the site include collaborations or agreements involving Biogen, Merck, AbbVie, Bristol-Myers Squibb, Mitsubishi Tanabe, and Eli Lilly).
Fundraising structuring and asset-centric vehicle formation
Assists in structuring financing and asset-centric vehicles for portfolio assets (site references include formation of asset-centric vehicles such as F-star Alpha/Beta).
Equity financing (early-stage and growth)
Provides early-stage and growth capital to life science companies; supports fundraising rounds (examples on the site include seed and Series A financings).
Strategic guidance and domain expertise
Provides strategic and operational guidance to portfolio companies, including development strategy and long-term company support as cited in portfolio testimonials.
Partnership and collaboration facilitation
Facilitates corporate collaborations, research partnerships and licensing arrangements between portfolio companies and pharmaceutical partners (examples on the site include collaborations or agreements involving Biogen, Merck, AbbVie, Bristol-Myers Squibb, Mitsubishi Tanabe, and Eli Lilly).
Fundraising structuring and asset-centric vehicle formation
Assists in structuring financing and asset-centric vehicles for portfolio assets (site references include formation of asset-centric vehicles such as F-star Alpha/Beta).
Portfolio
MPH described as an early investor whose support was transformative in company genesis.
#RNA biology / therapeutics
Multiple corporate collaborations and licensing options reported (Merck, Boehringer Ingelheim, AbbVie, Bristol-Myers Squibb); site references formation of asset-centric vehicles (F-star Alpha/Beta) and large Series A financing.
#Biologics / bispecific antibodies / immuno-oncology
Founding team cites leveraging MPH's network and expertise; MPH was an early investor.
#Biotechnology / therapeutics
Developing oral small-molecule degraders of extracellular proteins; site lists completion of a $12M seed financing.
#Small-molecule therapeutics / protein degraders
Site references multiple collaborations and license agreements involving Covagen.
#Biologics / bispecific fynomabs
Site references completed fundraising and adoption of a program by Amed.
#Gene editing / therapeutics (implied by name and site context)
MPH described as an early investor whose support was transformative in company genesis.
#RNA biology / therapeutics
Multiple corporate collaborations and licensing options reported (Merck, Boehringer Ingelheim, AbbVie, Bristol-Myers Squibb); site references formation of asset-centric vehicles (F-star Alpha/Beta) and large Series A financing.
#Biologics / bispecific antibodies / immuno-oncology
Founding team cites leveraging MPH's network and expertise; MPH was an early investor.
#Biotechnology / therapeutics
Developing oral small-molecule degraders of extracellular proteins; site lists completion of a $12M seed financing.
#Small-molecule therapeutics / protein degraders
Site references multiple collaborations and license agreements involving Covagen.
#Biologics / bispecific fynomabs
Site references completed fundraising and adoption of a program by Amed.
#Gene editing / therapeutics (implied by name and site context)